Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David H. Ebb, M.D.

Co-Author

This page shows the publications co-authored by David Ebb and Leonard Kaban.
Connection Strength

0.807
  1. Genetic Analysis of Giant Cell Lesions of the Maxillofacial and Axial/Appendicular Skeletons. J Oral Maxillofac Surg. 2017 Feb; 75(2):298-308.
    View in: PubMed
    Score: 0.175
  2. Adjuvant Antiangiogenic Treatment for Aggressive Giant Cell Lesions of the Jaw: A 20-Year Experience at Massachusetts General Hospital. J Oral Maxillofac Surg. 2017 Jan; 75(1):105-118.
    View in: PubMed
    Score: 0.174
  3. Do histologic criteria predict biologic behavior of giant cell lesions? J Oral Maxillofac Surg. 2012 Nov; 70(11):2573-80.
    View in: PubMed
    Score: 0.129
  4. Adjuvant antiangiogenic therapy for giant cell tumors of the jaws. J Oral Maxillofac Surg. 2007 Oct; 65(10):2018-24; discussion 2024.
    View in: PubMed
    Score: 0.095
  5. Antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws. J Oral Maxillofac Surg. 2002 Oct; 60(10):1103-11; discussion 1111-3.
    View in: PubMed
    Score: 0.067
  6. Denosumab for craniofacial fibrous dysplasia: duration of efficacy and post-treatment effects. Osteoporos Int. 2021 Sep; 32(9):1889-1893.
    View in: PubMed
    Score: 0.061
  7. Giant Cell Lesions of the Maxillofacial Skeleton Express RANKL by RNA In Situ Hybridization Regardless of Histologic Pattern. Am J Surg Pathol. 2019 06; 43(6):819-826.
    View in: PubMed
    Score: 0.053
  8. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a. Pediatrics. 1999 Jun; 103(6 Pt 1):1145-9.
    View in: PubMed
    Score: 0.053
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.